{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:40:34Z","timestamp":1791999634604,"version":"4.4.0"},"reference-count":60,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Although several case reports and small clinical trials have reported promising outcomes with Janus kinase (JAK) inhibitors for vitiligo, high\u2010quality evidence and guidelines are lacking. We evaluated the efficacy and safety of JAK inhibitors for the treatment of vitiligo using a meta\u2010analysis of randomized controlled trials (RCTs). We searched the PubMed, Embase, and Cochrane Library databases up to August 2023, with additional studies from <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> and company websites. We assessed outcomes, including percentage improvement in total vitiligo area score index (TVASI) and facial vitiligo area score index (FVASI); the proportion of patients achieving 50% improvement in TVASI (TVASI50) and 50% and 75% improvement in FVASI (FVASI50 and FVASI75); the risk of treatment\u2010emergent adverse events (TEAEs), serious adverse events (SAEs), infections, and skin\u2010related adverse events (AEs). Five studies with 1,550 participants were included. JAK inhibitors were associated with a higher proportion of TVASI50 (relative risk [RR] 2.67, 95% confidence interval [CI] 1.24\u20135.78) and FVASI75 (RR 3.97, 95%CI 2.62\u20136.02) responders than placebo. JAK inhibitors significantly increased the risk of skin\u2010related AEs (RR 1.96, 95% CI 1.29\u20132.98) compared with placebo. However, the risk of TEAEs, SAEs, and infections was not significantly different between the JAK inhibitor and placebo groups. Subgroup analysis showed that JAK1 and JAK1\/2 inhibitors were more effective than JAK3 inhibitors. However, there was insufficient evidence to suggest that the route of administration affects the efficacy and safety of JAK inhibitors in vitiligo. These findings indicate that JAK inhibitors are effective in repigmentation and well tolerated in patients with vitiligo.<\/jats:p>","DOI":"10.1002\/cpt.3538","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T12:00:58Z","timestamp":1734955258000},"page":"659-669","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"117","author":[{"given":"Fan","family":"Huang","sequence":"first","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6398-4743","authenticated-orcid":false,"given":"Dingyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaying","family":"Fan","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"},{"name":"Department of Clinical Pharmacy Xuzhou Medical University  Xuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxing","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"},{"name":"Department of Clinical Pharmacy Xuzhou Medical University  Xuzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-250X","authenticated-orcid":false,"given":"Diqin","family":"Yan","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ding","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Niu","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-2176","authenticated-orcid":false,"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences Peking University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-5829","authenticated-orcid":false,"given":"Yi","family":"Fang","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08868-z"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13418"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14001"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2023.2193329"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00447-y"},{"key":"e_1_2_11_10_1","first-page":"1639","article-title":"Current concepts of vitiligo immunopathogenesis","volume":"10","author":"Hla\u010da N.","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_12_1","unstructured":"AbbVie.A study to assess adverse events and effectiveness of Upadacitinib Oral tablets in adult and adolescent participants with vitiligo (Viti\u2010up)(2023) <https:\/\/clinicaltrials.gov\/study\/NCT06118411?cond=vitiligo&term=Upadacitinib&rank=1>."},{"key":"e_1_2_11_13_1","unstructured":"Incyte.A study to evaluate efficacy and safety of Povorcitinib in participants with nonsegmental vitiligo (STOP\u2010V1)(2023) <https:\/\/clinicaltrials.gov\/study\/NCT06113445?cond=vitiligo&term=Povorcitinib&limit=10&rank=2>."},{"key":"e_1_2_11_14_1","unstructured":"Incyte.A study to evaluate efficacy and safety of Povorcitinib in participants with nonsegmental vitiligo (STOP\u2010V2)(2023) <https:\/\/clinicaltrials.gov\/study\/NCT06113471?cond=vitiligo&term=Povorcitinib&limit=10&rank=1>."},{"key":"e_1_2_11_15_1","unstructured":"Arcutis Biotherapeutics.Safety and efficacy of ARQ\u2010252 cream 0.3% in subjects with non\u2010segmental facial vitiligo(2021) <https:\/\/clinicaltrials.gov\/study\/NCT04811131?term=NCT04811131&rank=1>."},{"key":"e_1_2_11_16_1","unstructured":"Incyte.Incyte Announces U.S. FDA Approval of Opzelura\u2122 (ruxolitinib) Cream for the Treatment of Vitiligo(2022) <https:\/\/investor.incyte.com\/news\u2010releases\/news\u2010release\u2010details\/incyte\u2010announces\u2010us\u2010fda\u2010approval\u2010opzeluratm\u2010ruxolitinib\u2010cream\u20100>."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/15593258221105370"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12661"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15070"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.042"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18606"},{"key":"e_1_2_11_23_1","unstructured":"Aclaris Therapeutics.A study of ATI\u201050002 topical solution for the treatment of vitiligo(2018) <https:\/\/clinicaltrials.gov\/study\/NCT03468855?cond=vitiligo&term=ATI\u201050002&limit=10&rank=1>."},{"key":"e_1_2_11_24_1","unstructured":"Pfizer.A 52\u2010week study to learn about the safety and effects of Ritlecitinib in participants with nonsegmental vitiligo (Tranquillo LTE)(2024) <https:\/\/clinicaltrials.gov\/study\/NCT06163326?cond=vitiligo&term=Ritlecitinib&limit=10&rank=1>."},{"key":"e_1_2_11_25_1","unstructured":"Pfizer.A 104\u2010week study of Ritlecitinib Oral capsules in adults with nonsegmental vitiligo (active and stable) Tranquillo 2 (Tranquillo 2)(2023) <https:\/\/clinicaltrials.gov\/study\/NCT06072183?cond=vitiligo&term=Ritlecitinib&limit=10&rank=2>."},{"key":"e_1_2_11_26_1","unstructured":"Pfizer.A 52\u2010week study of Ritlecitinib Oral capsules in adults and adolescents with nonsegmental vitiligo (active and stable) Tranquillo (Tranquillo)(2022) <https:\/\/clinicaltrials.gov\/study\/NCT05583526?cond=vitiligo&term=Ritlecitinib&limit=10&rank=3>."},{"key":"e_1_2_11_27_1","unstructured":"Dermavant Sciences GmbH.Safety and tolerability study of Cerdulatinib gel 0.37% in adults with vitiligo(2020) <https:\/\/clinicaltrials.gov\/study\/NCT04103060?cond=vitiligo&term=Cerdulatinib&limit=10&rank=1>."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13572"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.017"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.03.017"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.04.014"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.011"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.005"},{"key":"e_1_2_11_40_1","unstructured":"Incyte.Incyte announces data from phase 2b study evaluating Povorcitinib (INCB54707) in patients with extensive nonsegmental vitiligo(2023) <https:\/\/investor.incyte.com\/news\u2010releases\/news\u2010release\u2010details\/incyte\u2010announces\u2010data\u2010phase\u20102b\u2010study\u2010evaluating\u2010povorcitinib>."},{"key":"e_1_2_11_41_1","unstructured":"AbbVie.AbbVie Announces Upadacitinib (RINVOQ\u00ae) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3(2023) <https:\/\/www.prnewswire.com\/news\u2010releases\/abbvie\u2010announces\u2010upadacitinib\u2010rinvoq\u2010met\u2010the\u2010primary\u2010endpoint\u2010in\u2010phase\u20102\u2010clinical\u2010trial\u2010of\u2010vitiligo\u2010as\u2010program\u2010advances\u2010to\u2010phase\u20103\u2010301954354.html>."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1735615"},{"key":"e_1_2_11_43_1","first-page":"2897","article-title":"Jak inhibitors in vitiligo: a meta analysis","volume":"136","author":"Huang X.","year":"2023","journal-title":"Chin. Med. J."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13432"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.880"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00752-8"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17013"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1016"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04215.x"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.004"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_11_53_1","article-title":"Janus kinase inhibitors and adverse events of acne","volume":"18","author":"Martinez J.","year":"2023","journal-title":"JAMA Dermatol."},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106359"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b00677"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20351"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01062-9"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.016"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T21:18:29Z","timestamp":1740345509000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cpt.3538"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3538","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"2024-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}